The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
As the GLP-1 gold rush enters its most aggressive phase,
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Late on Monday night in California — 10:30 p.m. PT
The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech
Lila’s Nvidia-backed raise is about more than money. It is
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
In a strategic move poised to reshape the landscape of
AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results
Obesity remains a critical public health challenge in the United
MOST POPULAR
